ERBB2 and salivary duct carcinoma: A phase 2 multicenter study of Nanoxel®-PM and trastuzumab-pkrb (biosimilar to trastuzumab, a mAb against HER2) combination therapy in HER2-positive advanced salivary duct carcinoma demonstrated promising antitumor activity with a manageable toxicity profile [116].